Loading clinical trials...
Loading clinical trials...
A Three Arm, Randomized, Double-Blind, Multicenter, Phase 3 Study of HLX10(Anti-PD-1 Antibody) in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04(Avastin Biosimilar) Compared With Carboplatin+Pemetrexed in 1L Stage IIIB/IIIC or IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Conditions
Interventions
HLX10, an engineered anti-PD-1 antibody
HLX04, a bevacizumab biosimilar
+2 more
Locations
1
China
Cancer Hospital Chinese Academy of Medical Sciences (CAMS)
Beijing, Beijing Municipality, China
Start Date
December 2, 2019
Primary Completion Date
October 1, 2023
Completion Date
March 15, 2024
Last Updated
August 8, 2023
NCT05039801
NCT05058651
NCT03375307
NCT03647358
NCT05053971
NCT05372640
Lead Sponsor
Shanghai Henlius Biotech
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions